Program
QLS32015
A development code.
Its studies are mostly in Multiple Myeloma, led by Qilu Pharmaceutical.
Furthest: phase 3, since Aug 13, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 22 open or running | phase 3since Aug 13, 2025 | Jun 15, 2023 | Dec 2027phase 3 · NCT07138209 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 15, 2023First study: phase 1 study in RecurrenceFirst studyNCT05920876 · 100 planned · China
- Aug 13, 2025Phase 3 study in RecurrenceNCT07138209 · 228 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in RecurrenceNCT07138209
TargetBeta
“QLS32015 is a GPRC5D × CD3 bispecific antibody.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 3 |
| MBS314 for Injectionrule | beijing-mabworks-biotech-co-ltd | phase 2 | 1 |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07138209Recurrence · China | 3 | Recruiting | Dec 2027 | 228 |
| NCT05920876Recurrence · China | 1 | Recruiting | Dec 31, 2024 | 100 |
How it is read
Names in the registry
- “QLS32015”, 2 entries
Codes read as this program: QLS32015.
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.